BRIEF—Increased manufacturing capacity for COVID-19 Vaccine Janssen. India's Biological E. to produce J&J COVID-19 vaccine. Takeda and IDT. OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced a mutual agreement with IDT Biologika GmbH (“IDT”), a contract development and manufacturing organization, to utilize capacity at IDT previously reserved for Takeda’s dengue vaccine candidate (TAK-003) to manufacture the single-shot COVID-19 vaccine developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. At the end of a three-month period, the capacity will be returned to Takeda to resume critical manufacturing for the planned launch of its dengue vaccine, subject to regulatory approvals. “We are pleased to work with IDT to support Janssen’s efforts to make its COVID-19 vaccine available and accessible to as much of the world as possible,” said Rajeev Venkayya, President, Global Vaccine Business Unit at Takeda.
“We also recognize the massive unmet need for a dengue vaccine and will work closely with IDT to mitigate the impact on the supply of TAK-003.” Merck. March 2, 2021 4:30 pm EST KENILWORTH, N.J. --(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today it has entered into multiple agreements to support efforts to expand manufacturing capacity and supply of SARS-CoV-2/COVID-19 medicines and vaccines. The Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), will provide Merck with funding of up to $268.8 million to adapt and make available a number of existing manufacturing facilities for the production of SARS-CoV-2/COVID-19 vaccines and medicines. “We are steadfast in our commitment to contribute to the global response to the pandemic as part of the remarkable efforts of the entire medical and scientific community,” said Mike Nally, executive vice president, Human Health at Merck.
Janssen (Nederland) Biological E (India) Statement on Johnson & Johnson’s Collaboration in India with Biological E to Expand Manufacturing Capabilities For its COVID-19 Vaccine Candidate By Sarthak Ranade, Managing Director, Janssen India August 13, 2020 We are pleased to collaborate with Biological E. Limited on the manufacturing of our investigational SARS-CoV-2 vaccine candidate, Ad26.COV2.S.
This agreement for the technology transfer of our COVID-19 vaccine candidate to Biological E. further expands our capabilities to deliver on our goal to make our vaccine available to citizens around the world, provided it is proven to be safe and effective. For more than 70 years, Johnson & Johnson has been advancing healthcare in India, and this proposed collaboration further reinforces the company’s long-standing commitment to India.
India contributes to more than 60% of the global vaccine supply and is well positioned to play a key role in supporting large-scale vaccine production to combat the global pandemic. NeCEN (University of Leiden) The Phase 3 clinical trial results of the promising Covid-19 vaccine of Johnson & Johnson are expected this month. The Dutch electron microscopy facility NeCEN helped develop the company’s vaccine, and they have now published their scientific findings in Nature Communications. Freezing microscopes Already in January 2020, Johnson & Johnson started working on a coronavirus vaccine. The lion’s share of the work has been done by Janssen Pharmaceutica, a Belgium-based division of Johnson & Johnson, which also has a branch at the Leiden Bio Science Park in the Netherlands.
‘We have been working with Janssen for the past four years,’ says head of NeCEN Ludovic Renault. Spiky proteins Before we dive into how NeCEN helped Janssen with their vaccine, let’s have a look at the scientific approach of the pharmaceutical company. So far for the similarities. Helping hand In order to develop their vaccine, Janssen had to produce a specific type of spike protein, the so-called S-trimer. Efficient vaccine. Emergent Biosolutions (Baltimore) Emergent will provide contract development and manufacturing services beginning in 2021 to produce drug substance at large scale for commercial manufacturing with first two years valued at approximately For the remaining three years beginning in 2023, Emergent will provide a flexible capacity deployment model to support annual dose requirements , (GLOBE NEWSWIRE) -- (NYSE:EBS) today announced a five-year manufacturing services agreement with , one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for large-scale drug substance manufacturing for Johnson & Johnson’s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac® technology.
Emergent will provide contract development and manufacturing (CDMO) services to produce drug substance at large scale over five years, valued at approximately for the first two years. “We are proud to deploy our manufacturing strength to address the COVID-19 pandemic,” said ., president and chief executive officer of .